Champions Oncology (CSBR) Cash from Operations Growth (5y) (2015 - 2026)
Champions Oncology (CSBR) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -0.18% |
| Jan 31, 2026 | -64.15% |
| Oct 31, 2025 | -31.78% |
| Jul 31, 2025 | 23.21% |
| Apr 30, 2025 | 21.96% |
| Jan 31, 2025 | 11.92% |
| Oct 31, 2024 | -22.74% |
| Jul 31, 2024 | 25.51% |
| Apr 30, 2024 | -55.89% |
| Jan 31, 2024 | -22.51% |
| Oct 31, 2023 | 55.88% |
| Jul 31, 2023 | -69.23% |
| Apr 30, 2023 | -139.55% |
| Jan 31, 2023 | 28.73% |
| Oct 31, 2022 | 65.08% |
| Jul 31, 2022 | 36.89% |
| Apr 30, 2022 | 14.87% |
| Jan 31, 2022 | 52.41% |
| Oct 31, 2021 | 60.31% |
| Jul 31, 2021 | 15.87% |